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Abstract 
Objective 
Chronic diabetic peripheral neuropathic pain (DPNP) is difficult to treat, with treatment 
regimens often inadequate at controlling pain and limited by side-effects and drug tolerance. 
Secondary parameters such as quality of sleep and mood may also be important for successful 
DPNP management.  The objectives were to compare the analgesic efficacy of pregabalin, 
amitriptyline and duloxetine, and their effect on polysomnographic sleep, daytime 
functioning and quality of life in patients with DPNP. 
Research Design and Methods 
This was a double-blind, randomised, parallel group investigation of type 1 and 2 diabetic 
subjects with DPNP. Each treatment group had a single-blind, 8 day, placebo run in followed 
by 14 days lower dose and 14 days higher dose medication. At the end of each dose titration 
period subjective pain, sleep and daytime functioning were assessed during a two-day 
residential period.  
Results 
All medications reduced pain when compared with placebo but no one treatment was superior 
to any other. For sleep; pregabalin improved sleep continuity (P < 0·001) whereas duloxetine 
increased wake and reduced total sleep time (P < 0·01 and P < 0·001). Despite negative 
effects on sleep, duloxetine enhanced CNS arousal and performance on sensory motor tasks. 
There were no significant safety findings however there was a significantly higher number of 
adverse events in the pregabalin treatment group.  
 
 
 
Conclusions 
There was no significant difference in analgesic efficacy between amitriptyline, duloxetine 
and pregabalin.  However, there were significant differences in the secondary parameters 
which may be of relevance when deciding the optimal treatment for DPNP.  
Introduction 
Chronic diabetic peripheral neuropathic pain (DPNP) is a common, debilitating and 
distressing complication of diabetes mellitus.1 In addition to directly causing pain, it also can 
impair an individuals’ sleep, lower mood and have a negative impact on daily activities 
resulting in poor quality of life.2,3 In addition, the financial costs of chronic DPNP are 
substantial from both a direct healthcare cost and loss of productivity by the sufferers. 4  
Chronic DPNP is often difficult to treat, with drug regimes often being inadequate at 
controlling pain and limited by side-effects and the development of tolerance.5 First-line 
treatments for neuropathic pain include the tricyclic antidepressant (TCA) amitriptyline, the 
selective serotonin and noradrenaline reuptake inhibitor (SNRI) duloxetine, and calcium 
channel alpha 2 delta ligands such as pregabalin and gabapentin.6,7 Although amitriptyline 
has been shown to be efficacious in the treatment of neuropathic pain8 its relative non-
specific mode of action may limit its use due a broad range of adverse effects.9  Duloxetine 
has been reported to be safe and effective in patients with DPNP10 with a relatively low rate 
of adverse events.11  The anticonvulsant pregabalin has also been shown to be effective in the 
treatment of DPNP.12  Side effects associated with this agent include somnolence; however, it 
has been suggested that pregabalin’s positive effect on sleep may lead to further improvement 
of pain and quality of life.13 
For patients with diabetes sleep can be affected by a number of factors including increased 
nocturia14, sleep disordered breathing15, periodic limb movements16, and episodes of hyper or 
hypo-glycaemia.17, 18 In addition for patients with DPNP sleep may also be affected by pain. 2, 
3 , 19
 
Pregabalin has been shown to consistently improve subjective sleep in patients with DPNP20 
and studies in healthy volunteers suggest that this agent also enhances slow wave sleep.21 The 
aim of this study was to assess the effects of three first line treatments for DPNP on pain, 
sleep, cognitive function and quality of life, and to investigate whether the improved 
restorative sleep seen in healthy individuals was replicated in patients with chronic DPNP.   
Research Design and Methods 
Subjects 
Subjects aged 18 years and above, with diabetes mellitus (type 1 or type 2) for at least one 
year and neuropathic pain of diabetic origin were invited to participate in the study.  Subjects 
were recruited on the basis of symptoms suggestive of DPNP, including one or more of the 
following- dysaesthesia, burning pain, cold or heat allodynia, shooting or lancinating pains 
and hyperalgesia affecting both lower extremities at any level below the mid-thighs.  A 
confirmation of DPNP was then made by means of a Leeds Assessment of Neuropathic 
Symptoms and Signs (LANSS)22 score >12.  Subjects were excluded if there was evidence of 
cognitive impairment (score of <25 on the Mini Mental State Exam (MMSE)), end stage 
disease of a major system, evidence of a recurrent and/or severe hypoglycaemic event, 
(defined as hypoglycaemia requiring help from a third party), in the last 3 years, or a recent 
cardiac or cerebral ischaemic event. Pregnant or breast-feeding women and subjects with a 
history of dependence on or abuse of alcohol/recreational drugs were also excluded. 
Furthermore, subjects were not allowed to enter the study if they had been involved in 
another clinical trial within the previous three months.  
Subjects were reimbursed for their time and inconvenience and at the end of the study were 
provided with the study medication to which they had been randomized if this was requested. 
This trial was conducted according to ICH-GCP guidelines at the Surrey Clinical Research 
Centre (Surrey CRC), Faculty of Health and Medical Sciences, University of Surrey, UK.  
The study received a favourable opinion from the Essex 1 Research Ethics Committee and 
University of Surrey Ethics Committee and was registered at clinicaltrials.gov, with 
registration number NCT00370656. All participants supplied written informed consent before 
screening. 
Procedures 
The trial was a double-blind, randomised, parallel group investigation with an eight day 
single-blind placebo run in. Subjects were sequentially randomized into one of the three 
treatment arms (pregabalin, amitriptyline, or duloxetine).  The randomisation was provided 
by an independent statistician to ensure that groups were matched for age and gender where 
possible.  Patients were stratified into four groups: males 18-59 yrs; females 18-59 yrs; male 
>60 yrs; females >60 yrs. All participants were requested to stop taking their current pain 
medication (for the equivalent of at least five half-lives) before participating in the trial. For 
ethical reasons, subjects were allowed to continue taking opioids and non-steroidal anti-
inflammatory drugs during the study and were allowed to take paracetamol with a maximum 
dose of 4 g /day.  
After the eight-day placebo run in, subjects were titrated through 14 days of lower dose 
medication (amitriptyline 25 mg bd; duloxetine 60 mg om; pregabalin 150 mg bd) to 14-days 
of higher dose medication (amitriptyline 25 mg om, 50 mg on; duloxetine 60 mg bd; 
pregabalin 300 mg bd).  At the end of each treatment period subjects were resident at the 
Surrey CRC for a 48 hour comprehensive assessment of polysomnographic (PSG) sleep, 
subjective pain, daytime functioning and continuous glucose monitoring (CGMS® System 
GoldTM Medtronic MiniMed, Inc. (figure 1)).  
 
 
Outcomes 
Primary outcome 
The primary outcome was subjective pain as assessed by the Brief Pain Inventory (BPI). 
Secondary outcomes 
Quality of life was assessed using short-form 36-item general health survey (SF-36)23 at 
screening and again on the last day of treatment (day 36). Each residential visit was identical, 
with a PSG habituation night to familiarize patients with the environment, followed by a PSG 
assessment night. Subjects were trained and re-familiarised on the psychometric test battery 
the day after their habituation night and baseline or treatment cognitive function and daytime 
sleepiness were assessed the following day.  
Subjective pain was assessed by means of the Brief pain inventory (BPI)24 and a visual 
analogue scale adapted from the Short Form McGill Pain Questionnaire.25 
Subjective sleep, mood and daytime sleepiness were assessed by the visual analogue scales: 
Leeds Sleep Evaluation Questionnaire (LSEQ)26, Linear Analogue Rating Scales (LARS)27, 
and Karolinska Sleepiness Scale (KSS).28 
PSG sleep records were manually staged according to Rechtschaffen and Kales criteria.29 For 
clinical sleep variables (periodic limb movements and apnoea / hypopnoea index), only 
placebo and higher dose (period three) records were manually staged. 
Psychomotor performance and cognitive functioning were assessed by means of 
psychometric test battery including:- 
Sensori-motor and psychomotor speed: Continuous Tracking task, CTT,27 and Choice 
Reaction Time task, CRT.27  
CNS arousal and information processing tasks: Critical Flicker Fusion, CFF 27, Stroop task 
and Digit Symbol Substitution Test, DSST.30  
Working and explicit memory tasks: Immediate and Delayed Word Recall 31  and Sternberg’s 
Short-term Memory Scanning Task, STM.32  
Statistical analysis 
No reliable data were available to enable a formal calculation of the sample size of patients 
needed for an 80% power to show statistical significant (5%-level, double-sided) difference 
between treatments on the primary endpoint of subjective pain (BPI). However, comparable 
single-site studies investigating amitriptyline and gabapentin (a compound closely related to 
pregabalin) in DPNP successfully used around 30 patients for each comparison.9, 33   
The main analysis was done according to a pre-planned statistical analysis plan. The safety 
population was defined as consisting of the set of those subjects who were randomised onto 
the trial, and received at least one administration of study medication. This population was 
used for the summary of safety data and baseline characteristics. The evaluable population 
was defined as consisting of those subjects who completed the study. The data set was 
analysed in a linear mixed model. The observations were the dependent variable and fixed 
effect was treatment with visits being a repeated measure. Subjects were added as a random 
effect. Additional independent covariates included body mass index (BMI) and age. 
Statistical significance level was set to 5% (p < 0.05). All analyses were done with SAS® 
PROC MIXED 9.1 software. 
Role of the funding source 
The funding source was a research investigator led grant from Pfizer Ltd. Pfizer did not 
participate in data collection, data analysis, data interpretation or writing of the report. 
Results 
A total of 104 subjects with both type 1 and 2 DM were screened between Febuary 2007 and 
March 2009, and 83 enrolled and randomised. Follow up visits took place between April 
2007 and May 2009. A total of 65 subjects (78%) completed all treatment periods and were 
considered the evaluable population used for the main analysis. Table 1 shows the 
demographic characteristics of all subjects randomised to the trial. Twenty-seven were 
randomised to pregabalin, 28 to duloxetine and 28 to amitriptyline. All subjects were 
Caucasian, and an equal number of males (n = 19) and females (n = 9) were randomised to 
each treatment arm except in the pregabalin arm (females, n = 8). Mean BMI and mean age 
were similar across all three treatment groups.  
Pain 
The primary outcome of subjective pain showed no significant difference between the 
treatment groups. Amitriptyline, duloxetine and pregabalin reduced BPI severity, BPI 
interference and VAS pain when compared with placebo baseline, with no one treatment 
showing superiority to another (Table 2).   
Subjective sleep 
Subjects in the pregabalin arm had improved ease of getting to sleep and improved quality of 
sleep at day 36, compared with placebo baseline, however there was no significant difference 
between treatments on any of the subjective sleep components. 
 
 
 
PSG sleep 
Sleep Continuity 
There was a significant treatment by visit effect on measures of sleep continuity with 
duloxetine significantly showing worse effect than pregabalin and amitriptyline (pregabalin 
and amitriptyline not statistically distinguishable). Compared with placebo baseline, 
duloxetine (60 mg and 120 mg) worsened sleep through reduced sleep efficiency (SE) 
(P < 0·0001 and P < 0·05, respectively), reduced total sleep time (TST) (P < 0·0001 and P < 
0·05, respectively and increased wake after sleep onset (WASO) (P < 0·01).  In contrast, 
compared with placebo baseline pregabalin (600 mg) significantly increased SE and TST and 
reduced WASO (P < 0·01 for all). Amitriptyline (50 mg and 75 mg) had no significant effect 
on SE and TST but did, at the higher dose (75 mg), reduce WASO (P < 0·05) (Table 3).  
Sleep Architecture 
There was no significant treatment by visit effect on non-rapid eye movement sleep (NREM) 
(Table 3). 
For rapid eye movement (REM) sleep there was a significant difference between treatments 
with clear evidence that loss of REM sleep (reduced REM duration, % REM and REM 
cycles) was more pronounced in the duloxetine treatment group compared with pregabalin 
and amitriptyline (the latter two not statistically distinguishable) (P < 0·01, P < 0·05 and 
P < 0·0001, respectively) (Table 3). 
Clinical Sleep 
There was a significant treatment by visit effect for periodic limb movements (PLM) per hour 
of sleep (P < 0·001) and apnoea hypopnoea index (AHI) (P < 0·0001) (Table 3). 
Pregabalin (600 mg) significantly reduced PLM index compared with placebo baseline 
(P < 0·001) whereas duloxetine (P < 0·05) and amitriptyline (P < 0·01) increased PLM index 
(the latter two not statistically distinguishable) (Table 3).  
For apnoeas and hypopnoeas, pregabalin significantly increased AHI compared with placebo 
baseline (P < 0·001).  Duloxetine and amitriptyline had no distinguishable effect on AHI.  
Pregabalin also increased the number of oxygen desaturations / hr (≥ 4%) (P < 0·001) but did 
not affect mean nocturnal oxygen saturation (Table 3). 
Daytime function 
There was no significant treatment by visit effect on memory tasks (STM, IWR, DWR) 
(Table 2).   
There was a significant difference between treatments and improved daytime performance for 
duloxetine and amitriptyline. Duloxetine and amitriptyline improved reaction time on the 
psychomotor CRT task with reduced recognition (RRT) and total (TRT) reaction time (RRT: 
P < 0·0001 and P < 0·05; TRT: P < 0·0001 and P < 0·01, respectively for both low and 
higher dose).  There was also evidence that duloxetine improved CNS arousal and 
information processing ability with an increased CFF threshold (P < 0·0001 at both doses) 
(Table 2).  There was however no evidence of improved information processing ability on the 
DSST and Stroop task (Table 2). 
There was evidence of impairment of daytime functioning with pregabalin on the sensori-
motor, CTT (P < 0·01) task, with pregabalin (300 mg and 600 mg) increasing tracking error 
compared with duloxetine and amitriptyline. 
 
 
Quality of life and Subjective Daytime Ratings 
There was no significant treatment by visit effect on any quality of life component (SF-36) or 
SF-36 summary score (Table 2).  
There were no differences between treatment groups on subjective measures of mood, 
co-ordination and sedation (LARS and KSS) and no change on any of these variables with 
time. 
Safety 
There was no overall significant treatment by visit effect for overall blood glucose but there 
were significant differences between treatments on nocturnal glucose.  Duloxetine (60 mg 
and 120 mg) was associated with a small but significant decrease in nocturnal blood glucose 
(mean, P < 0·01 and area under the curve, AUC, P < 0·05) (Table 3).  Pregabalin (600 mg 
only) was associated with a small but significant increase in nocturnal blood glucose (mean, 
P < 0·01, AUC P < 0·05 and % measurements > 15 mmol / L, P < 0·01) (Table 3). 
No changes of note were seen in vital signs, biochemistry parameters or ECGs.  There were 
no clinically significant changes in haematology parameters except that one patient 
experienced a fall in platelet count which may have been due to amitriptyline treatment. 
There were six serious adverse events (SAEs), one death and five non-fatal SAEs. None of 
the SAEs were considered to be related to study medication.  Ten subjects withdrew 
prematurely as a result of an adverse event (six from the pregabalin treatment group, three 
from the duloxetine group and one from the amitriptyline group).  Subjects in the pregabalin 
treatment group recorded the highest number of treatment-emergent adverse events (P < 
0·0001) with a causal relationship to study drug.  These events were related to general and 
nervous system disorders and specifically fatigue, dizziness and somnolence.  Twenty-five 
subjects asked to continue with their medication at the end of the trial (eleven pregabalin, 
eight amitriptyline, and six duloxetine). 
Discussion 
The three study medications, amitriptyline, duloxetine and pregabalin, all reduced subjective 
pain with no one drug being superior to another over the four-week, dose titration period.  
Subjective pain ratings (BPI severity) showed approximately 50% improvement, in line with 
previous studies.8,12   
Daytime performance measures showed no evidence of cognitive impairment during 
treatment, with the exception of increased tracking error on a divided attention task (CTT) 
with pregabalin.  Previous studies have indicated that use of amitriptyline may be limited by 
its effects on daytime functioning, in particular aspects of memory function which are 
disrupted even after long-term dosing.34 The study reported here suggests that there is limited 
evidence for cognitive function being compromised with amitriptyline treatment and all three 
treatments were relatively well tolerated.  The change in tracking (CTT) performance with 
pregabalin replicated a similar finding reported previously in healthy volunteers35 and 
supports current clinical evidence that daytime effects from pregabalin treatment are limited. 
There was evidence that duloxetine improved attention-based tasks and sensori-motor 
performance.  Similar improvements with SNRIs and selective serotonin reuptake inhibitors 
(SSRIs) in mental processing speed have been observed in both patients with depression and 
healthy volunteers36  possibly reflecting CNS activation. 
PSG sleep examination gave further support to a CNS-activating effect of duloxetine as both 
the 60 mg and 120 mg dose reduced total sleep time, increased the amount of wake, increased 
time to fall asleep and substantially disrupted REM sleep.  In contrast, sleep continuity was 
promoted by pregabalin (600 mg) and unchanged with amitriptyline.  The signature changes 
in sleep seen with duloxetine have previously been reported, although the alerting effect has 
been associated more with evening dosing.37 Despite previous literature suggesting that 
amitriptyline promotes sleep initiation and sleep continuity38, our results indicated little 
impact of amitriptyline on sleep in patients with DPNP.  In line with previous reports, 
pregabalin improved sleep continuity, reducing wake after sleep onset.  
The sleep fragmentation seen with duloxetine is concerning.  It is widely believed that poor 
sleep may worsen pain and although duloxetine has good analgesic efficacy its effectiveness 
may be limited by this physiological effect.  In addition to a direct effect on sleep there was 
also evidence that periodic limb movements were significantly increased under duloxetine 
and amitriptyline, a finding often reported for antidepressant drugs.39 Pregabalin, on the other 
hand, significantly reduced PLM.  One clinical finding that requires further investigation was 
the apparent increase in apnoea hypopnoea index and increase in oxygen desaturations with 
pregabalin during sleep.  This clinical finding has not been reported previously although 
Saletu-Zhylarz et al., (2006) did report an increase in snoring index.40 It should be noted that 
there was a relatively low incidence of sleep apnoea in the patient population and overall the 
increase in AHI was numerical rather than increasing clinical severity. 
As significant changes in sleep and daytime functioning were observed it was perhaps 
surprising to find that there were no significant improvements in mental health as assessed by 
the SF-36 following 28 days of treatment.  All 3 treatments (pregabalin for generalised 
anxiety disorder, duloxetine and amitriptyline for depression) are indicated for affective 
disorders and it has been well documented that DPNP is associated with low mood, 
depression and anxiety.2,3  Although the SF-36 had been a tool used in previous DPNP 
studies10 it is possible that this measure was not sensitive enough to assess changes in mood 
over a short, 4 week, period.  Mood scales such as Profile of Mood States (POMS) might be a 
more appropriate measure to detect subtle changes in mood state over a shorter period of 
time.    
Overall all three treatments were well tolerated with no significant laboratory or safety 
findings.  There was no indication of changes in HDL values with duloxetine as has been 
reported by other authors.11  One patient had clinically significant haematological changes 
with amitriptyline (platelet count reducing from 253,000 to 87,000 x 109 / L), reinforcing the 
need for care when prescribing the tricylcic antidepressant in older adults.  In general all 
adverse events were in line with those previously reported however there was a significantly 
higher number of adverse events reported in the pregabalin treatment group, in particular 
those related to nervous system disorders such as fatigue, somnolence and dizziness.  
Although patients reported a higher number of adverse events with pregabalin, and this 
should be considered when prescribing pregabalin to DPNP patients, it should be noted that a 
higher proportion of patients requested to continue with pregabalin treatment at the end of the 
study suggested that the adverse events did not interfere significantly with their activities of 
daily living. 
In conclusion, amitriptyline, duloxetine and pregabalin were equally effective analgesic 
medications in patients with DPNP.  Pregabalin promoted sleep whereas duloxetine increased 
sleep fragmentation and substantially reduced REM sleep.  Daytime function was relatively 
unaffected by drug treatment and all three drugs were well tolerated.  In this short, 28-day 
dosing study, there was no evidence of improved quality of life (SF-36) even with the sleep 
enhancement observed with pregabalin. Further longer term studies, with more sensitive 
measures of assessment, may help establish the effect of sleep changes seen with pregabalin 
and duloxetine on pain, glycaemic control, and quality of life during long term treatment. 
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 Table 1 
 
 Pregabalin Duloxetine Amitriptyline All 
 
 
N = 27 N = 28 N = 28 N = 83 
Gender Males 19 19 19 57 
 
Females 8 9 9 26 
Age (years) Mean (SD) 66.3 (7.5) 65.0 (9.6) 64.2 (9.6) 65.1 (8.9) 
BMI (kg/m2) Mean (SD) 32.1 (5.2) 32.0 (5.5) 31.9 (5.6) 32.0 (5.4) 
Cholesterol* 
(mmol/L) 
Mean (SD) 5.7 (0.9) 4.3 (1.1) 4.2 (1.2) 4.2 (1.1) 
HDL*   
(mmol/L) 
Mean (SD) 1.2 (0.4) 1.2 (0.3) 1.1 (0.3) 1.2 (0.3) 
LDL*   
(mmol/L) 
Mean (SD) 1.8 (0.8) 2.0 (0.8) 1.8 (0.9) 1.9 (0.8) 
Triglycerides*  
(mmol/L) 
Mean (SD) 2.5 (1.4) 2.4 (2.0) 2.8 (1.5) 2.6 (0.6) 
HbA1c (%) Mean (SD) 7.7 (1.6) 7.9 (1.5) 8.2 (1.4) 7.9 (1.5) 
Duration of 
diabetes (years) 
Mean (SD) 15.2 (16.6) 13.8 (8.7) 13.8 (8.7) 14.2 (11.8) 
Type of Diabetes  Type 1DM 5 4 2 11 
 
Type 2DM 22 24 26 72 
Diabetes 
treatment  
Insulin 14 18 20 52 
 
Diabetic 
Medication 
10 9 8 27 
 
Diet Only 3 1 0 4 
Ethnicity Caucasian 27 28 28 83 
Table 1 shows basic demography of randomised patients.  Data is derived from the screening 
visit except for values marked * where only post study values were available. 
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Table 2 
 Treatment Pregabalin Duloxetine Amitriptyline 
Task by Visit Mean Mean Mean 
 Effect (SE) (SE) (SE) 
  
Plc Low dose High dose Plc Low dose High dose Plc Low dose High dose 
Subjective Pain & 
QoL 
 
         
N  24 21 19 23 23 23 27 24 23 
BPI Severity NS  3.1   2.3*  2.4   3.4   2.5**   2.2*   3.5   2.7*   2.6  
 
 
 (0.4)  (0.4)  (0.4)  (0.5)  (0.4)  (0.4)  (0.4)  (0.4)  (0.4) 
BPI Interference on  NS  3.1   2.7**   2.9*   3.9   3.3*   2.5**   3.8   2.7**   2.0**  
Sleep 
 
 (0.5)  (0.6)  (0.7)  (0.7)  (0.7)  (0.6)  (0.5)  (0.6)  (0.5) 
VAS NS  16.8   13.5*   13.2   23.3   16.3**   13.2***   29.6   22.3**   23.6  
 
 
 (2.0)  (2.1)  (1.7)  (2.5)  (2.3)  (2.2)  (2.3)  (2.1)  (2.4) 
SF36 Mental  NS  52.8    52.4   50.2     51.0   51.1     51.7  
Component Summary 
 
 (9.3)    (10.0)  (9.0)    (8.8)  (7.3)    (8.0) 
SF36 Physical  NS  34.2     31.1   37.8     36.6   39.5     38.5  
Component Summary 
 
 (8.2)    (10.9)  (10.0)    (9.4)  (9.3)    (8.8) 
           Cognitive Functioning           
N  25 21 17 21 20 23 26 23 23 
CTT MD P < 0.01  14.0   16.8**   19.6***   17.0   15.1   15.0   16.6   16.1   16.7  
 
 
 (0.6)  (1.4)  (1.7)  (1.4)  (1.0)  (1.1)  (1.0)  (0.9)  (1.2) 
CRT TRT P < 0.05  871.7   768.6   780.8   812.6   752.4***   726.5***   808.1   773.9**   750.3**  
 
 
 (30.4)  (19.5)  (17.1)  (75.8)  (13.5)  (12.5)  (15.2)  (14.7)  (13.6) 
CFF P < 0.001  27.1   27.4   26.9*   28.0   30.0***   30.1***   27.2   26.8   27.2  
 
 
 (0.3)  (0.2)  (0.2)  (0.3)  (0.3)  (0.3)  (0.2)  (0.3)  (0.2) 
Stroop VR NS  68.6   68.2   68.5   67.2   70.1*   69.8*   68.2   68.7   69.2  
 
 
 (0.4)  (0.7)  (0.5)  (0.8)  (0.2)  (0.2)  (0.5)  (0.6)  (0.4) 
DSST Correct NS  28.6   32.1   32.1   29.1   31.3**   32.0**   27.7   29.9***   31.3***  
 
 
 (0.8)  (0.9)  (0.9)  (0.9)  (0.9)  (0.9)  (0.9)  (1.1)  (1.2) 
STM RT NS  838.6   768.3***   795.6   911.6   860.8***   829.7***   845.2   800.2***   771.4**  
 
 
 (13.9)  (15.5)  (20.8)  (14.2)  (12.7)  (12.7)  (17.2)  (14.5)  (14.2) 
IWR Correct NS  7.0   7.5   7.3   7.5   7.5   7.6   6.3   6.0   5.4**  
 
 
 (0.2)  (0.3)  (0.3)  (0.4)  (0.3)  (0.3)  (0.3)  (0.3)  (0.3) 
DWR Correct NS  2.7   3.4   3.2   4.1   4.3   4.1   3.0   2.5   2.3*  
 
 
 (0.2)  (0.3)  (0.3)  (0.3)  (0.3)  (0.3)  (0.3)  (0.3)  (0.2) 
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Table 2 shows patients’ general well-being through subjective assessments and daytime performance measures.    
Subjective assessments included the mean pain scores for Brief Pain Inventory (BPI) pain severity, BPI pain interference on sleep and visual analogue scale as well as quality 
of life (QoL) (SF-36) changes.  There was no significant treatment by time effects for any of the pain variables or on SF-36 scores.   
Cognitive function assessment included: CTT = Continuous tracking test; CFF = Critical flicker fusion; CRT = Choice reaction time; TRT = Total reaction time; VR = Valid 
responses; STM = Sternberg short-term memory scanning task; RT = reaction time; DSST = Digit symbol substitution test; IWR = Immediate word recall; DWR = Delayed 
word recall.  
N = number of records included in the analysis.  Treatment by visit effect is detailed where a significant difference between treatments was observed.  NS means that there 
was no significant difference between the three treatment groups.   
Individual treatments (low and high dose) were compared with placebo baseline.  Where there was a significant change in time from placebo baseline this is shown as an 
asterix against individual treatment means. * P < 0.05, ** P < 0.01, *** P < 0.001 and **** P < 0.0001  
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Table 3 
  Pregabalin Duloxetine Amitriptyline 
 Treatment Mean Mean Mean 
 by Visit 
Effect 
(SE) (SE) (SE) 
  
Plc Low dose High dose Plc Low dose High dose Plc Low dose High dose 
PSG Sleep           
N  25 21 17 21 20 23 27 23 23 
TST (min) P < 0.001  371.6  380.6  410.3**   381.4   338.1****  356.6*   368.6   378.3   393.8  
 
 
 (11.8)  (9.1)  (10.2)  (9.4)  (12.1)  (13.8)  (8.9)  (12.0)  (10.9) 
SE (%) P < 0.001  77.3   79.2   85.4**   79.4   70.4****   74.2*   76.7   78.7   82.0  
 
 
 (2.5)  (1.9)  (2.1)  (2.0)  (2.5)  (2.9)  (1.9)  (2.5)  (2.3) 
WASO (min) P < 0.01  90.9   81.8   57.2**   85.6   120.2**   100.5   91.0   78.8   66.6*  
 
 
 (11.8)  (8.8)  (10.3)  (9.0)  (11.0)  (12.8)  (9.4)  (12.2)  (10.8) 
Duration of Non-REM  P = 0.0526  291.5   319.0**   348.3****   298.0   303.3   326.7*   291.6   328.6****   343.6****  
sleep (min) 
 
 (10.6)  (8.9)  (10.1)  (9.6)  (10.7)  (12.6)  (7.4)  (10.0)  (9.3) 
Duration of REM (min) P < 0.01  80.1   61.6**   62.0**   83.4   34.8****   29.9****   77.0   49.7****   50.2****  
 
 
 (6.0)  (6.8)  (6.9)  (7.5)  (5.2)  (5.7)  (5.2)  (6.5)  (5.4) 
Number of REM  P < 0.0001  3.3   2.8*   3.1   3.8   1.5****   1.8****   3.7   2.7***   2.3****  
periods 
 
 (0.2)  (0.3)  (0.3)  (0.3)  (0.2)  (0.2)  (0.2)  (0.3)  (0.2) 
PLMS Index (PLM /  P < 0.001  19.7     12.0**   16.2     24.4*   16.2     19.9**  
hour of sleep) 
 
 (4.5)    (4.1)  (3.6)    (6.2)  (4.6)    (4.9) 
AHI P < 0.0001  5.8     11.9***   3.7     2.3   3.6     2.9  
 
 
 (1.6)    (3.5)  (0.8)    (0.6)  (0.8)    (0.9) 
Mean number of  P < 0.0001  3.9     10.2***   2.9     1.9   2.8     2.3  
desaturations (>4%) /  
 
 (1.0)   (3.2)  (0.7)    (0.6)  (0.6)    (0.7) 
hour of sleep 
 
         
           Blood Glucose           
N  24 21 17 21 20 23 27 23 23 
Mean Nocturnal Blood  P < 0.01  7.1   7.4   8.7**   8.1   6.8**   7.0*   8.3   7.5   7.9  
Glucose (mmol / L) 
 
 (0.4)  (0.6)  (0.7)  (0.5)  (0.4)  (0.4)  (0.4)  (0.5)  (0.4) 
Nocturnal Glucose:  P < 0.05  3395.3   3518.0   4185.1*   3844.3   3253.6**   3361.5*   3959.9   3620.0   3802.6*  
AUC (minsmmol / L) 
 
 (188.1)  (308.2)  (317.2)  (234.9)  (183.5)  (190.2)  (173.4)  (233.7)  (178.7) 
Mean % of nocturnal  P < 0.05  0.0   5.5*   3.2**   0.9   0.9   0.1   0.3   0.8   0.6  
glucose levels 
 
 (0.0)  (3.8)  (2.3)  (0.9)  (0.9)  (0.1)  (0.2)  (0.8)  (0.6) 
> 15.0 mmol/L 
 
         
 26
Table 3 shows assessment of polysomnographic (PSG) sleep and nocturnal blood glucose.  PSG sleep continuity and sleep architecture variables included: TST = Total sleep 
time; SE% = Sleep efficiency; WASO = Wake after sleep onset; REM = Rapid eye movement.  Clinical sleep variables included AHI = Apnoea hypopnoea index and PLMS 
= Periodic Limb Movements.  Nocturnal blood glucose measurements included mean and AUC = Area under the curve.  
N = number of records included in the analysis.  Treatment by visit effect is detailed where a significant difference between treatments was observed.  NS means that there 
was no significant difference between the three treatment groups.   
Individual treatments (low and high dose, where applicable) were compared with placebo baseline.  Where there was a significant change in time from placebo baseline this 
is shown as an asterix against individual treatment means. * P < 0.05, ** P < 0.01, *** P < 0.001 and **** P < 0.0001
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Figure Legends 
 
Figure 1: A Schematic diagram illustrating the timing of the main study procedures.  BPI =  Brief Pain 
Inventory, CGMS = Continuous Glucose Monitoring System, GTB = Guildford Test Battery (Continuous 
tracking test; Critical flicker fusion; Choice reaction time; Stroop Test; Sternberg short-term memory scanning 
task; DSST = Digit symbol substitution test; Word Recall; Leeds Sleep Evaluation Questionnaire and Linear 
Analogue Scales), PSG = Polysomnography. 
 
GTB Training was at 10:00, 13:00 and 16:00 on Day 7, 21 and 35.  GTB Testing was at 08:00, 10:00, 13:00 and 
16:00 on Day 8, 22 and 36. 
